Literature DB >> 6502518

Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration.

K L Brouwer, H B Kostenbauder, P J McNamara, R A Blouin.   

Abstract

The pharmacokinetics of the enzyme inducer, phenobarbital, was evaluated in genetically obese and lean Zucker and lean Sprague-Dawley rats. The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter). Standardizing the volume of distribution for total body weight in the obese and lean Zucker and lean Sprague-Dawley rats resulted in similar volume terms. Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr). Greater differences in phenobarbital clearance were observed when clearance was corrected for body weight. Whether comparing the absolute or standardized pharmacokinetic data, lean and obese Zucker rats will exhibit 2- to 3-fold higher phenobarbital plasma concentrations after administration of a standard 75- to 100-mg/kg enzyme-inducing regimen relative to Sprague-Dawley rats. Pharmacokinetic parameters from the single dose study were used to calculate appropriate phenobarbital doses (21-58 mg/kg/12 hr) to achieve similar steady-state phenobarbital plasma concentrations after chronic oral administration in all three groups of rats. Steady-state phenobarbital clearance values were not significantly different from clearance values after single dose administration in each group of rats. The dramatic intra- and inter-strain alterations in phenobarbital disposition demonstrated in this study explain the high mortality reported in Zucker rats after administration of traditional enzyme induction doses of phenobarbital. Differences in phenobarbital disposition should be considered in enzyme induction studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502518

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Phenobarbital pharmacokinetics in obesity. A case report.

Authors:  L Wilkes; L H Danziger; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Authors:  B C Israel; R A Blouin; W McIntyre; S I Shedlofsky
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

3.  Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats.

Authors:  Ellen Q Wang; Ho-Leung Fung
Journal:  AAPS PharmSci       Date:  2002

Review 4.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

5.  Modification of inflammatory processes by phenobarbital in rats.

Authors:  F E Levy; L Chauvelot-Moachon; I Florentin; M Forest; C Poüs; C Fournier; J P Giroud
Journal:  Inflammation       Date:  1991-12       Impact factor: 4.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.